Global Hemoglobinopathies Market Size, Share & Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Regional Outlook and Forecast,

Global Hemoglobinopathies Market Size, Share & Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Regional Outlook and Forecast, 2022 - 2028

The Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.

In its stable state, normal human hemoglobin’s are tetrameric protein composed of two globin chains, each of which has an alpha (α-like) chain and a beta (β-like) chain. Every globin chain is attached to a heme moiety that contains iron. The synthesis of alpha-like and beta-like (also known as non-alpha-like) is maintained throughout the lifetime, so their ratio remains constant. In the human body, hemoglobin is used to transport oxygen from the lungs to tissues.

This happens as the globin chains enable the molecules to take up more oxygen in places with high oxygen concentrations and release oxygen in areas with low oxygen concentrations. Hemoglobin also transports carbon dioxide and nitric oxides. Hemoglobinopathies are a set of hereditary diseases. In these diseases, there is an abnormal synthesis or structure of the hemoglobin molecules.

For example, one such blood condition caused due to unstable hemoglobin that deforms or damages the red blood cells is called sickle cell disease (SCD). The unusual red blood cell breakdown causes anemia and clogs the blood vessels, leading to multi-organ ischemic damage and acute pain. Millions of individuals are affected by SCD, especially those whose ancestral origin is from Western Hemisphere (Central America, Caribbean, and South America), Sub-Saharan Africa, India, Saudi Arabia, and Mediterranean counties like Greece, Italy, and Turkey.

Bone marrow transplants and blood stem cells are used to treat Children with sickle cell disease. The clinical intensity of SCD varies, ranging from minor problems that sometimes go unnoticed to severe effects that need urgent hospitalization. There are medications for symptomatic effects. Also, newborn screening (NBS) can help discover SCD to lessen some of the disease’s impact on children and newborns.

COVID – 19 Impact Analysis

The COVID-19 pandemic has affected nearly all industries; it has forced healthcare organizations to concentrate the majority of funds and time on fighting COVID-19, due to a significant drop in the hemoglobinopathies market and many other sectors, especially in health and pharmaceutical, was reported. The interruptions in treating hemoglobinopathy patients were primarily due to the risk of infection in the hospitals. Special health needs are required for patients with hemoglobinopathy. The demand for several drugs and treatments has significantly increased during the pandemic. Still, due to the shutdown of factories and other restrictions, production was unable to meet the required needs.

Market Growth Factors

The rising cases of hemoglobinopathy in under-developed countries

There is a limitation in data related to the exact number of inherited hemoglobin illnesses, but still, they are certainly going to be a major burden for healthcare resources. The public healthcare system in under-developed countries is also improving, and with that, the survival rate of children suffering from these diseases is also increasing, which means more patients will be available for later treatments. Inherited hemoglobin disorder is considered to be the most common monogenic illness.

High investments in research and development

The growth of tissue-oriented, safe, and efficient gene editing technology has contributed to the development of various gene therapy types for hemoglobin-related illnesses. Gene therapy has the potential to treat patients. As new and promising therapeutic options appear, the overall cost of treatment is expected to get more affordable. Presently, an increasing number of trials to find the efficiency and safety of these gene editing and addition technologies to rescue hemoglobin production in beta laminopathies are going on.

Market Restraining Factors

Failure of the clinical trials and high risk in treatment

A hematopoietic stem cell transplant is currently the only available treatment for Sickle Cell Disease. This approach has evolved enough to have resulted in practice guidelines for its indication and management. But despite the numerous protocols, the number of patients treated with them is only a few. Moreover, the long-term side effects of solid tumors in transplanted Sickle cell patients are also an area of concern. Although there is constant advancement in the medical sector, there is still a lack of permanent treatment for hemoglobinopathy illness.

Type Outlook

Based on the Type, the Hemoglobinopathy Market is segmented into Thalassemia, Sickle Cell Disease and Others. The thalassemia segment acquired the highest revenue share in the hemoglobinopathies market in 2021. It is because thalassemia is a type of blood disorder that is caused by the alteration in the gene. There are two primary types of thalassemia. One is alpha thalassemia which occurs when the alpha globin protein gene or genes are missing or mutated. And the other one is Beta thalassemia which is due to the change in the production of beta globin protein.

Distribution Channel Outlook

By Distribution channel, the is classified into Hospital Pharmacy, Online Providers and Drug Stores and Retail Pharmacy. The Hospital pharmacy segment recorded a significant revenue share in the hemoglobinopathies market in 2021. Due to the composition of the healthcare services, which includes the practice, preparing, compounding, storing, dispensing medicines and medical devices, and patient counseling. Also, they have healthcare professionals like doctors and nurses for effective, safe, and efficient use. In health facilities, a hospital pharmacy is a specialized field of pharmacy which is a part of the patient’s health care.

Therapy Outlook

On the basis of Therapy, the hemoglobinopathy market is divided into Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea and Others. The Monoclonal Antibody Medication segment procured the largest revenue share in the hemoglobinopathy market in 2021. It is because of the sufficient medications available for the therapy and also because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are similar to antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.

Regional Outlook

Region-wise, the hemoglobinopathies market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the hemoglobinopathies market in 2021. Due to the awareness programs initiated by the different organizations in which they spread awareness about the diseases related to hemoglobinopathy and the need to research and find new therapies for its treatment. Also, the rising immigration to the region from areas where this disease is widely found and the availability of new and enhanced medications are expected to fuel the market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Thalassemia
  • Sickle Cell Disease
  • Others
By Distribution Channel
  • Drug Stores & Retail Pharmacy
  • Hospital Pharmacy
  • Online Providers
By Therapy
  • Monoclonal Antibody Medication
  • Hydroxyurea
  • ACE Inhibitors
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Abbott Laboratories
  • Sanofi S.A.
  • Danaher Corporation
  • Pfizer, Inc. (Global Blood Therapeutics, Inc.)
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Alnylam Pharmaceuticals, Inc.
  • Emmaus Life Sciences, Inc.
  • Biogen, Inc.
  • Canthera Discovery Ltd.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Hemoglobinopathies Market, by Type
1.4.2 Global Hemoglobinopathies Market, by Distribution Channel
1.4.3 Global Hemoglobinopathies Market, by Therapy
1.4.4 Global Hemoglobinopathies Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Hemoglobinopathies Market by Type
3.1 Global Thalassemia Market by Region
3.2 Global Sickle Cell Disease Market by Region
3.3 Global Others Market by Region
Chapter 4. Global Hemoglobinopathies Market by Distribution Channel
4.1 Global Drug Stores & Retail Pharmacy Market by Region
4.2 Global Hospital Pharmacy Market by Region
4.3 Global Online Providers Market by Region
Chapter 5. Global Hemoglobinopathies Market by Therapy
5.1 Global Monoclonal Antibody Medication Market by Region
5.2 Global Hydroxyurea Market by Region
5.3 Global ACE Inhibitors Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Hemoglobinopathies Market by Region
6.1 North America Hemoglobinopathies Market
6.1.1 North America Hemoglobinopathies Market by Type
6.1.1.1 North America Thalassemia Market by Country
6.1.1.2 North America Sickle Cell Disease Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Hemoglobinopathies Market by Distribution Channel
6.1.2.1 North America Drug Stores & Retail Pharmacy Market by Country
6.1.2.2 North America Hospital Pharmacy Market by Country
6.1.2.3 North America Online Providers Market by Country
6.1.3 North America Hemoglobinopathies Market by Therapy
6.1.3.1 North America Monoclonal Antibody Medication Market by Country
6.1.3.2 North America Hydroxyurea Market by Country
6.1.3.3 North America ACE Inhibitors Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Hemoglobinopathies Market by Country
6.1.4.1 US Hemoglobinopathies Market
6.1.4.1.1 US Hemoglobinopathies Market by Type
6.1.4.1.2 US Hemoglobinopathies Market by Distribution Channel
6.1.4.1.3 US Hemoglobinopathies Market by Therapy
6.1.4.2 Canada Hemoglobinopathies Market
6.1.4.2.1 Canada Hemoglobinopathies Market by Type
6.1.4.2.2 Canada Hemoglobinopathies Market by Distribution Channel
6.1.4.2.3 Canada Hemoglobinopathies Market by Therapy
6.1.4.3 Mexico Hemoglobinopathies Market
6.1.4.3.1 Mexico Hemoglobinopathies Market by Type
6.1.4.3.2 Mexico Hemoglobinopathies Market by Distribution Channel
6.1.4.3.3 Mexico Hemoglobinopathies Market by Therapy
6.1.4.4 Rest of North America Hemoglobinopathies Market
6.1.4.4.1 Rest of North America Hemoglobinopathies Market by Type
6.1.4.4.2 Rest of North America Hemoglobinopathies Market by Distribution Channel
6.1.4.4.3 Rest of North America Hemoglobinopathies Market by Therapy
6.2 Europe Hemoglobinopathies Market
6.2.1 Europe Hemoglobinopathies Market by Type
6.2.1.1 Europe Thalassemia Market by Country
6.2.1.2 Europe Sickle Cell Disease Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Hemoglobinopathies Market by Distribution Channel
6.2.2.1 Europe Drug Stores & Retail Pharmacy Market by Country
6.2.2.2 Europe Hospital Pharmacy Market by Country
6.2.2.3 Europe Online Providers Market by Country
6.2.3 Europe Hemoglobinopathies Market by Therapy
6.2.3.1 Europe Monoclonal Antibody Medication Market by Country
6.2.3.2 Europe Hydroxyurea Market by Country
6.2.3.3 Europe ACE Inhibitors Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Hemoglobinopathies Market by Country
6.2.4.1 Germany Hemoglobinopathies Market
6.2.4.1.1 Germany Hemoglobinopathies Market by Type
6.2.4.1.2 Germany Hemoglobinopathies Market by Distribution Channel
6.2.4.1.3 Germany Hemoglobinopathies Market by Therapy
6.2.4.2 UK Hemoglobinopathies Market
6.2.4.2.1 UK Hemoglobinopathies Market by Type
6.2.4.2.2 UK Hemoglobinopathies Market by Distribution Channel
6.2.4.2.3 UK Hemoglobinopathies Market by Therapy
6.2.4.3 France Hemoglobinopathies Market
6.2.4.3.1 France Hemoglobinopathies Market by Type
6.2.4.3.2 France Hemoglobinopathies Market by Distribution Channel
6.2.4.3.3 France Hemoglobinopathies Market by Therapy
6.2.4.4 Russia Hemoglobinopathies Market
6.2.4.4.1 Russia Hemoglobinopathies Market by Type
6.2.4.4.2 Russia Hemoglobinopathies Market by Distribution Channel
6.2.4.4.3 Russia Hemoglobinopathies Market by Therapy
6.2.4.5 Spain Hemoglobinopathies Market
6.2.4.5.1 Spain Hemoglobinopathies Market by Type
6.2.4.5.2 Spain Hemoglobinopathies Market by Distribution Channel
6.2.4.5.3 Spain Hemoglobinopathies Market by Therapy
6.2.4.6 Italy Hemoglobinopathies Market
6.2.4.6.1 Italy Hemoglobinopathies Market by Type
6.2.4.6.2 Italy Hemoglobinopathies Market by Distribution Channel
6.2.4.6.3 Italy Hemoglobinopathies Market by Therapy
6.2.4.7 Rest of Europe Hemoglobinopathies Market
6.2.4.7.1 Rest of Europe Hemoglobinopathies Market by Type
6.2.4.7.2 Rest of Europe Hemoglobinopathies Market by Distribution Channel
6.2.4.7.3 Rest of Europe Hemoglobinopathies Market by Therapy
6.3 Asia Pacific Hemoglobinopathies Market
6.3.1 Asia Pacific Hemoglobinopathies Market by Type
6.3.1.1 Asia Pacific Thalassemia Market by Country
6.3.1.2 Asia Pacific Sickle Cell Disease Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Hemoglobinopathies Market by Distribution Channel
6.3.2.1 Asia Pacific Drug Stores & Retail Pharmacy Market by Country
6.3.2.2 Asia Pacific Hospital Pharmacy Market by Country
6.3.2.3 Asia Pacific Online Providers Market by Country
6.3.3 Asia Pacific Hemoglobinopathies Market by Therapy
6.3.3.1 Asia Pacific Monoclonal Antibody Medication Market by Country
6.3.3.2 Asia Pacific Hydroxyurea Market by Country
6.3.3.3 Asia Pacific ACE Inhibitors Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Hemoglobinopathies Market by Country
6.3.4.1 China Hemoglobinopathies Market
6.3.4.1.1 China Hemoglobinopathies Market by Type
6.3.4.1.2 China Hemoglobinopathies Market by Distribution Channel
6.3.4.1.3 China Hemoglobinopathies Market by Therapy
6.3.4.2 Japan Hemoglobinopathies Market
6.3.4.2.1 Japan Hemoglobinopathies Market by Type
6.3.4.2.2 Japan Hemoglobinopathies Market by Distribution Channel
6.3.4.2.3 Japan Hemoglobinopathies Market by Therapy
6.3.4.3 India Hemoglobinopathies Market
6.3.4.3.1 India Hemoglobinopathies Market by Type
6.3.4.3.2 India Hemoglobinopathies Market by Distribution Channel
6.3.4.3.3 India Hemoglobinopathies Market by Therapy
6.3.4.4 South Korea Hemoglobinopathies Market
6.3.4.4.1 South Korea Hemoglobinopathies Market by Type
6.3.4.4.2 South Korea Hemoglobinopathies Market by Distribution Channel
6.3.4.4.3 South Korea Hemoglobinopathies Market by Therapy
6.3.4.5 Singapore Hemoglobinopathies Market
6.3.4.5.1 Singapore Hemoglobinopathies Market by Type
6.3.4.5.2 Singapore Hemoglobinopathies Market by Distribution Channel
6.3.4.5.3 Singapore Hemoglobinopathies Market by Therapy
6.3.4.6 Malaysia Hemoglobinopathies Market
6.3.4.6.1 Malaysia Hemoglobinopathies Market by Type
6.3.4.6.2 Malaysia Hemoglobinopathies Market by Distribution Channel
6.3.4.6.3 Malaysia Hemoglobinopathies Market by Therapy
6.3.4.7 Rest of Asia Pacific Hemoglobinopathies Market
6.3.4.7.1 Rest of Asia Pacific Hemoglobinopathies Market by Type
6.3.4.7.2 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel
6.3.4.7.3 Rest of Asia Pacific Hemoglobinopathies Market by Therapy
6.4 LAMEA Hemoglobinopathies Market
6.4.1 LAMEA Hemoglobinopathies Market by Type
6.4.1.1 LAMEA Thalassemia Market by Country
6.4.1.2 LAMEA Sickle Cell Disease Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Hemoglobinopathies Market by Distribution Channel
6.4.2.1 LAMEA Drug Stores & Retail Pharmacy Market by Country
6.4.2.2 LAMEA Hospital Pharmacy Market by Country
6.4.2.3 LAMEA Online Providers Market by Country
6.4.3 LAMEA Hemoglobinopathies Market by Therapy
6.4.3.1 LAMEA Monoclonal Antibody Medication Market by Country
6.4.3.2 LAMEA Hydroxyurea Market by Country
6.4.3.3 LAMEA ACE Inhibitors Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Hemoglobinopathies Market by Country
6.4.4.1 Brazil Hemoglobinopathies Market
6.4.4.1.1 Brazil Hemoglobinopathies Market by Type
6.4.4.1.2 Brazil Hemoglobinopathies Market by Distribution Channel
6.4.4.1.3 Brazil Hemoglobinopathies Market by Therapy
6.4.4.2 Argentina Hemoglobinopathies Market
6.4.4.2.1 Argentina Hemoglobinopathies Market by Type
6.4.4.2.2 Argentina Hemoglobinopathies Market by Distribution Channel
6.4.4.2.3 Argentina Hemoglobinopathies Market by Therapy
6.4.4.3 UAE Hemoglobinopathies Market
6.4.4.3.1 UAE Hemoglobinopathies Market by Type
6.4.4.3.2 UAE Hemoglobinopathies Market by Distribution Channel
6.4.4.3.3 UAE Hemoglobinopathies Market by Therapy
6.4.4.4 Saudi Arabia Hemoglobinopathies Market
6.4.4.4.1 Saudi Arabia Hemoglobinopathies Market by Type
6.4.4.4.2 Saudi Arabia Hemoglobinopathies Market by Distribution Channel
6.4.4.4.3 Saudi Arabia Hemoglobinopathies Market by Therapy
6.4.4.5 South Africa Hemoglobinopathies Market
6.4.4.5.1 South Africa Hemoglobinopathies Market by Type
6.4.4.5.2 South Africa Hemoglobinopathies Market by Distribution Channel
6.4.4.5.3 South Africa Hemoglobinopathies Market by Therapy
6.4.4.6 Nigeria Hemoglobinopathies Market
6.4.4.6.1 Nigeria Hemoglobinopathies Market by Type
6.4.4.6.2 Nigeria Hemoglobinopathies Market by Distribution Channel
6.4.4.6.3 Nigeria Hemoglobinopathies Market by Therapy
6.4.4.7 Rest of LAMEA Hemoglobinopathies Market
6.4.4.7.1 Rest of LAMEA Hemoglobinopathies Market by Type
6.4.4.7.2 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel
6.4.4.7.3 Rest of LAMEA Hemoglobinopathies Market by Therapy
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Sanofi S.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Trials and Approvals:
7.3 Danaher Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Merck & Co., Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.6 Bristol Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Alnylam Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Emmaus Life Sciences, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Biogen, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Canthera Discovery Ltd.
7.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings